Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Durability of Vaccine-Induced and Natural Immunity Against COVID-19: A Narrative Review
Nick Pooley, Salim S. Abdool Karim, Béhazine Combadière, et al.
Infectious Diseases and Therapy (2023) Vol. 12, Iss. 2, pp. 367-387
Open Access | Times Cited: 67

Showing 26-50 of 67 citing articles:

Stronger and durable SARS-CoV-2 immune response to mRNA vaccines in 5–11 years old children with prior COVID-19
Costanza Di Chiara, Anna Cantarutti, Maria Raffaella Petrara, et al.
Vaccine (2023) Vol. 42, Iss. 2, pp. 263-270
Open Access | Times Cited: 6
The role of immune suppression in COVID-19 hospitalization: clinical and epidemiological trends over three years of SARS-CoV-2 epidemic
Marta Canuti, Maria Cristina Monti, Chiara Bobbio, et al.
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 5
Role Of Vaccines Against COVID-19 Pandemic
Professor Dr. Batool Mutar Mahdi, Mustafa Almukhtar
SLAS DISCOVERY (2023) Vol. 28, Iss. 8, pp. 355-357
Open Access | Times Cited: 4
COVID-19 Vaccine Efficacy Over Time: Severe Disease in Hospitalized Patients
Athol U. Wells
Radiology (2024) Vol. 310, Iss. 1
Closed Access | Times Cited: 1
Duration of antibody response to the receptor binding domain of SARS-CoV-2 in infected or vaccinated individuals – A one year retrospective cohort study
Martin Pasev, Angelina Trifonova, Andrey Velichkov, et al.
International Immunopharmacology (2024) Vol. 133, pp. 112084-112084
Open Access | Times Cited: 1
Healthcare workers’ willingness to receive COVID-19 booster dose and associated factors in the Democratic Republic of the Congo
Bertin Mindje Kolomba, François Kalenga Luhembwe, Deca Blood Banza Ndala, et al.
Human Vaccines & Immunotherapeutics (2024) Vol. 20, Iss. 1
Open Access | Times Cited: 1
Safety, reactogenicity, and immunogenicity of Ad26.COV2.S as homologous or heterologous COVID-19 booster vaccination: Results of a randomized, double-blind, phase 2 trial
Mathieu Le Gars, Jerald Sadoff, Vicky Cárdenas, et al.
Vaccine (2024) Vol. 42, Iss. 19, pp. 3938-3952
Open Access | Times Cited: 1
High-resolution kinetics and cellular determinants of SARS-CoV-2 antibody response over two years after COVID-19 vaccination
Rocío Rubio, Dídac Macià, Diana Barrios, et al.
Microbes and Infection (2024), pp. 105423-105423
Open Access | Times Cited: 1
Impact of Vaccination Status on COVID-19 Severity and Pulmonary Involvement
Sorina Maria Denisa Laitin, Luminița Bădițoiu, Ruxandra Laza, et al.
Medicina (2024) Vol. 60, Iss. 12, pp. 1919-1919
Open Access | Times Cited: 1
Longitudinal analysis of SARS-CoV-2 IgG antibody durability in Puerto Rico
Zachary J. Madewell, Nathan Graff, Velma K. Lopez, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 1
Community Level Correlates of COVID-19 Booster Vaccine Hesitancy in the United States: A Cross-Sectional Analysis
Henry Krasner, Nicolette Harmon, Jeffrey J. Martin, et al.
Vaccines (2024) Vol. 12, Iss. 2, pp. 167-167
Open Access | Times Cited: 1
Humoral immunity to SARS-CoV-2 in kidney transplant recipients and dialysis patients: IgA and IgG patterns unraveled after SARS-CoV-2 infection and vaccination
Caroline De Bouver, Jason Bouziotis, Veerle Wijtvliet, et al.
Virology Journal (2024) Vol. 21, Iss. 1
Open Access | Times Cited: 1
Determinants of Systemic SARS-CoV-2-Specific Antibody Responses to Infection and to Vaccination: A Secondary Analysis of Randomised Controlled Trial Data
Juana Claus, Thijs ten Doesschate, Esther Taks, et al.
Vaccines (2024) Vol. 12, Iss. 6, pp. 691-691
Open Access | Times Cited: 1
Beyond the peak: Global health post-COVID-19 and Mpox: Successes, challenges and prospects
Bashar Haruna Gulumbe, Zaharadeen Muhammad Yusuf, Nazeef Idris Usman
Microbes and Infectious Diseases /Microbes and Infectious Diseases (2023)
Open Access | Times Cited: 3
Safety and immunogenicity of VLPCOV-02, a SARS-CoV-2 self-amplifying RNA vaccine with a modified base, 5-methylcytosine, in healthy individuals
Masayuki Aboshi, Kenta Matsuda, Daisuke Kawakami, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 2
Systemic SARS-CoV-2-specific antibody responses to infection and to COVID-19 and BCG vaccination
Juana Claus, Thijs ten Doesschate, Esther Taks, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Snapshot of Anti-SARS-CoV-2 IgG Antibodies in COVID-19 Recovered Patients in Guinea
Solène Grayo, Houlou Sagno, Oumar Diassy, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 10, pp. 2965-2965
Open Access
Individual and familial factors associated with mRNA COVID-19 vaccine uptake in pregnancy: A large-scale registry-based linkage study
Jovan Elyass, Anteneh Desalegn, Nhung T. H. Trinh, et al.
Vaccine (2024) Vol. 42, Iss. 21, pp. 126171-126171
Open Access
Durability of SARS-CoV-2 IgG Antibodies: Insights from a Longitudinal Study, Puerto Rico
Zachary J. Madewell, Nathan Graff, Velma K. Lopez, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
New Evidence for SARS-CoV-2 Vaccine Boosting in Patients With Chronic Lung Diseases
Laura Fabbri, S Stanel
CHEST Journal (2024) Vol. 166, Iss. 4, pp. 655-656
Closed Access
Recent Vaccination Against SARS-CoV-2 Is Associated with Less Severe Disease in Working-Age Adults
Kailey Fischer, Joanne M. Langley, Robyn Harrison, et al.
International Journal of Environmental Research and Public Health (2024) Vol. 21, Iss. 11, pp. 1501-1501
Open Access
Comparative Analysis of Vaccine-induced Immunity and Natural Immunity in Post-COVID Patients
Saulesh S. Kurmangaliyeva, Akzhan M. Madenbayeva, Saltanat T. Urazayeva, et al.
West Kazakhstan Medical Journal (2024) Vol. 66, Iss. 4, pp. 387-400
Open Access
A Meta-analysis of Severe Acute Respiratory Syndrome Coronavirus 2 Anti-spike Immunoglobulin G Antibody Durability up to 9 Months After Full Vaccination in Adults
Maura C Dodge, Christina Ellervik, Yachana Kataria
Clinics in Laboratory Medicine (2024) Vol. 45, Iss. 1, pp. 111-136
Closed Access
Durability of Adaptive Immunity in Immunocompetent and Immunocompromised Patients Across Different Respiratory Viruses: RSV, Influenza, and SARS-CoV-2
Achilleas Livieratos, Lars Erik Schiro, Charalambos Gogos, et al.
Vaccines (2024) Vol. 12, Iss. 12, pp. 1444-1444
Open Access
Silenced Solutions: The Importance of COVID-19 Therapeutics and the Fight Against Suppression
Shaun Black
Medical Research Archives (2023) Vol. 11, Iss. 5
Open Access | Times Cited: 1

Scroll to top